Memorial Sloan Kettering Small Animal Imaging Research

纪念斯隆凯特琳小动物成像研究

• 批准号: 7120105
• 负责人: JASON Arthur KOUTCHER
• 金额: $ 79.7万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7120105
• 关键词: Rodentias; autoradiography; bioimaging /biomedical imaging; biomedical equipment development; biomedical equipment purchase; biomedical equipment resource; computed axial tomography; drug screening /evaluation; image processing; neoplasm /cancer radioimmunotherapy; neoplasm /cancer radionuclide diagnosis; nuclear magnetic resonance spectroscopy; optical tomography; positron emission tomography; radiopharmacology; radiotracer; single photon emission computed tomography; training

DESCRIPTION (provided by applicant): Research at Memorial Sloan Kettering Cancer Center is focused on cancer diagnosis and enhancing response to treatment. Because tumors are heterogeneous, both between individuals and within a single tumor, non-invasive imaging studies are necessary to provide information about variations in response. The main technologies we will focus on include nuclear magnetic resonance (NMR), positron emission tomography (PET), and optical imaging, although other instruments are part of the application. The 3 imaging techniques chosen were based on the fact that they will provide complementary information. NMR imaging provides high spatial resolution but modest functional data. PET and NMR spectroscopy have poorer spatial resolution but provide valuable chemical/metabolic information. Optical imaging can provide very sensitive imaging tools to detect very small numbers of cells and thus these modalities have different strengths. We focus on enhancing the ancillary/support services to maximize information available from the different studies. Image analysis/correlation is important since in most studies, multiple imaging studies are done and it is critical to spatially align different or longitudinal studies. The Synthetic Chemistry and Vector Cores are critical for developing novel tools for exploring signaling pathways, and molecular events related to oncogenesis, treatment, cell death and host toxicity. Enhancement of imaging techniques to maintain state of the art methodologies, improving current techniques, and converting imaging into a more quantitative science is vital. A wide range of oncologic issues will be studied to exploit these tools in developing newer and better targeted drugs, to minimize host toxicity, to develop standards of response criteria for cytostatic drugs and detect responses/failures earlier in the course of treatment. The range of projects studied include predicting tumor response to treatment, dosimetry for radioimmunotherapy, pharmacology, gene therapy and imaging, tumor metabolism, and evaluating responses to novel cytostatic agents. Research at MSKCC is translational and the goals of many of these projects are to be moved to the clinic in the shortest time feasible. Leadership will come from the imaging scientists (Drs. Koutcher, Blasberg and Larson) and also from the molecular pharmacology group who will meet monthly along with a Technology Committee, to decide which problems are important and appropriate to be addressed by imaging technology.

描述（由申请人提供）：在纪念斯隆开氏癌症中心进行的研究重点是癌症诊断和增强对治疗的反应。由于肿瘤是异质的，因此在个体和单个肿瘤之间，因此必须进行非侵入性成像研究，以提供有关反应变化的信息。我们将重点关注的主要技术包括核磁共振（NMR），正电子发射断层扫描（PET）和光学成像，尽管其他仪器是应用的一部分。所选的3种成像技术是基于它们将提供互补信息的事实。 NMR成像提供了高空间分辨率，但功能数据适中。 PET和NMR光谱的空间分辨率较差，但提供了有价值的化学/代谢信息。光学成像可以提供非常敏感的成像工具来检测非常少量的细胞，因此这些方式具有不同的强度。我们专注于增强辅助/支持服务，以最大程度地提高不同研究中可用的信息。图像分析/相关性很重要，因为在大多数研究中，进行了多项成像研究，并且在空间上对齐不同或纵向研究至关重要。合成化学和载体核心对于开发用于探索信号通路的新工具以及与肿瘤发生，治疗，细胞死亡和宿主毒性有关的分子事件至关重要。增强成像技术以保持艺术方法的状态，改善当前技术并将成像转化为更定量的科学是至关重要的。将研究各种肿瘤学问题，以利用这些工具开发新的，更好的靶向药物，以最大程度地减少宿主毒性，以制定细胞抑制药物的反应标准标准，并在治疗过程中早些时候检测反应/失败。研究的项目范围包括预测肿瘤对治疗的反应，用于放射免疫疗法，药理学，基因治疗和成像，肿瘤代谢以及评估对新细胞抑制剂的反应的剂量测定法。 MSKCC的研究是转化的，其中许多项目的目标应在最短的时间内移至诊所。领导力将来自成像科学家（Koutcher博士，Blasberg和Larson博士），也来自分子药理学小组，他们将与技术委员会每月开会，以确定哪些问题很重要且适合通过成像技术解决。

项目成果

Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.

• DOI: 10.2967/jnumed.111.092098
• 发表时间: 2011-10
• 期刊: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
• 作者: Ruggiero A;Holland JP;Hudolin T;Shenker L;Koulova A;Bander NH;Lewis JS;Grimm J
• 通讯作者: Grimm J

Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.

• DOI: 10.4161/cbt.8.20.9595
• 发表时间: 2009-10
• 期刊: Cancer biology & therapy
• 影响因子: 3.6
• 作者: Yang KM;Russell J;Lupu ME;Cho H;Li XF;Koutcher JA;Ling CC
• 通讯作者: Ling CC

2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.

• DOI: 10.2967/jnumed.109.064212
• 发表时间: 2009-10
• 期刊: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
• 作者: Pillarsetty N;Punzalan B;Larson SM
• 通讯作者: Larson SM

Broad-spectrum multi-modality image registration: from PET, CT, and MRI to autoradiography, microscopy, and beyond.

广谱多模态图像配准：从 PET、CT 和 MRI 到放射自显影、显微镜检查等。

• DOI: 10.1109/iembs.2006.259650
• 发表时间: 2006
• 期刊: Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
• 作者: Zanzonico,PB

Tumor-specific targeting with modified Sindbis viral vectors: evaluation with optical imaging and positron emission tomography in vivo.

改良辛德比斯病毒载体的肿瘤特异性靶向：体内光学成像和正电子发射断层扫描评估。

• DOI: 10.1007/s11307-012-0585-8
• 发表时间: 2013
• 期刊: Molecular imaging and biology
• 影响因子: 3.1
• 作者: Stelter,Lars;Tseng,Jen-Chieh;Torosjan,Armen;Levin,Brandi;Longo,ValerieA;Pillarsetty,Nagavarakishore;Zanzonico,Pat;Meruelo,Daniel;Larson,StevenM
• 通讯作者: Larson,StevenM